Atlas Trials

Cara Therapeutics, Inc.

24 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Cara Therapeutics, Inc.

RecordFirmDate
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (NCT05978063)Cara Therapeutics, Inc.2023-08-01
CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus (NCT05356403)Cara Therapeutics, Inc.2022-08-26
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (NCT05387707)Cara Therapeutics, Inc.2022-08-16
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus (NCT05342623)Cara Therapeutics, Inc.2022-05-17
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT) (NCT04706975)Cara Therapeutics, Inc.2021-01-11
CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients (NCT05533008)Cara Therapeutics, Inc.2019-12-31
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (NCT04018027)Cara Therapeutics, Inc.2019-06-29
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus (NCT03995212)Cara Therapeutics, Inc.2019-06-25
Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects (NCT04019574)Cara Therapeutics, Inc.2019-06-20
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (NCT03998163)Cara Therapeutics, Inc.2019-05-06
Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects (NCT03947970)Cara Therapeutics, Inc.2019-01-17
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (NCT03636269)Cara Therapeutics, Inc.2018-07-17
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus (NCT03617536)Cara Therapeutics, Inc.2018-07-05
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) (NCT03422653)Cara Therapeutics, Inc.2018-02-20

Track Cara Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.